Somatostatin in the Treatment of Acromegaly

  • Daryl A. Cottrell
  • Samuel Cataland
  • Thomas O’Dorisio
Part of the Contemporary Internal Medicine book series (COIM, volume 3)


A 43-year-old white male with a history of hypertension, diabetes mellitus, coronary artery disease, and acromegaly presented to our hospital for treatment of diabetic ketoacidosis. The patient was diagnosed with acromegaly and insulin-dependent diabetes mellitus 20 years prior to admission. At that time, he had an increase in hand size, foot size, changes in facial features, sweating, and weakness. Two attempts at surgical resection 13 and 16 years prior to admission using transfrontal and transsphenoidal approaches were unsuccessful since the tumor could not technically be reached. The patient was not compliant over subsequent years and although counseled, refused therapy for his pituitary tumor, specifically, radiation or pharmacologic agents.


Growth Hormone Pituitary Tumor Growth Hormone Secretion Growth Hormone Level Diabetic Ketoacidosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Asa SL, Scheithauer B, Bilbao J: A case for hypothalamic acromegaly: A clinicopathological study of six patients with hypothalamic gangliocytomas producing GHRF. J Clin Endocrinol Metab. 58:796–803, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    Warner B, Santen R, Page R: Growth hormone and prolactin secretion by a tumor of the pharyngeal pituitary. Arch Intern Med. 96:56–68, 1982.CrossRefGoogle Scholar
  3. 3.
    Melmed S, Ezrin C, Kovacs K: Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. Engl J Med. 312:9–17, 1985.CrossRefGoogle Scholar
  4. 4.
    Melmed S, Ziel F, Braunstein G: Medical management of acromegaly due to ectopic production of GHRH by a carcinoid tumor. J Clin Endocrinol Metab. 67:395–399, 1988.PubMedCrossRefGoogle Scholar
  5. 5.
    Barkan A: Acromegaly: Diagnosis and therapy. Endocrinol Metab Clin North Am. 18(2):277–310, 1989.PubMedGoogle Scholar
  6. 6.
    Ashcraft M, Hartzband P, Van Herle A: A unique growth factor in patients with acromegaloidism. J Clin Endocrinol Metab. 57:272–276, 1983.PubMedCrossRefGoogle Scholar
  7. 7.
    Billestrup N, Swanson LW, Vale WW: Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA. 83:6854–6857, 1986.PubMedCrossRefGoogle Scholar
  8. 8.
    Berelowitz M, Szabo M, Frohman L: Somatomedin C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 212:1279–1281, 1981.PubMedCrossRefGoogle Scholar
  9. 9.
    Dieguez C, Page M, Scanion M: Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol 28:109–143, 1988.Google Scholar
  10. 10.
    Dieguez C, Page M, Peters J, et al: Growth hormone and its modulation. JR Coll Physicians London. 22(2):84–91, 1988.Google Scholar
  11. 11.
    Barkan A, Stred S, Reno K, et al: Increased growth hormone pulse frequency in acromega ly. J Clin Endocrinol Metab. 69:1225–1233, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Layton M, Fudman E, Barkan A, et al: Acromegalic arthropathy: Characteristics and response to therapy. Arthritis Rheum. 31(8):1022–1027, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Bloom S: Acromegaly. Am J Med. 82(suppl 5B):88–91, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Barkan A, Beitins I, Kelch R: Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 67:69–73, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Lamberts S, Uitterlinden P, Schuijff P, et al: Therapy of acromegaly with Sandostatin: The predictive value of an acute test, the value of serum SmC measurements in dose adjustment and the definition of a biochemical “cure.” Clin Endocrinol. 29:411–420, 1988.CrossRefGoogle Scholar
  16. 16.
    Oyen W, Pieters G, Meijer E: Which factors predict the result of pituitary surgery in acromegaly? Acta Endocrinol. 117:491–496, 1988.PubMedGoogle Scholar
  17. 17.
    Lamberts S, Uitterlinden P, del Pozo E: SMS 201–995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 65:703–710, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Gorden P, Comi R, Maton P, Go V: NIH Conference: Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 110:35–50, 1989.PubMedCrossRefGoogle Scholar
  19. 19.
    Barkan A, Kelch R, Hopwood N, et al: Treatment of acromegaly with the long-acting somatostatin analog SMS 201–995. J Clin Endocrinol Metab. 66:16–23, 1988.PubMedCrossRefGoogle Scholar
  20. 20.
    Chiodini P, Cozzi R, Dallabonzana D, et al: Medical treatment of acromegaly with SMS 201–995, a somatostatin analog: A comparison with bromocriptine. J Clin Endocrinol Metab. 64:447–453, 1987.PubMedCrossRefGoogle Scholar
  21. 21.
    Sandier L, Burrin J, Williams G, et al: Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201–995). Clin Endocrinol. 26:85–95, 1987.CrossRefGoogle Scholar
  22. 22.
    Lamberts S, Verleun T, Hofland L, et al: A comparison between the effects of SMS 201–995, bromocriptine, and a combination of both drugs on hormone release by the cultured pituitary tumor cells of acromegalic patients. Clin Endocrinol. 27:11–23, 1987.CrossRefGoogle Scholar
  23. 23.
    Reubi J, Landolt A: The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 68:844–850, 1989.PubMedCrossRefGoogle Scholar
  24. 24.
    Barkan A, Lloyd R, Chandler W, et al: Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201–995 shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 67:1040–1048, 1988.PubMedCrossRefGoogle Scholar
  25. 25.
    Spinas G, Zapf J, Landolt A, et al: Preoperative treatment of 5 acromegalics with a somatostatin analogue: Endocrine and clinical observations. Acta Endocrinol. 114:249–256, 1987.PubMedGoogle Scholar
  26. 26.
    Barnard L, Grantham W, Lamberton P, et al: Treatment of resistant acromegaly with long-acting somatostatin analogue (SMS 201–995). Ann Intern Med. 105:856–861, 1986.PubMedCrossRefGoogle Scholar
  27. 27.
    Sandier L, Burrin J, Joplin G, et al: Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly. Br Med J. 296:751–752, 1988.CrossRefGoogle Scholar
  28. 28.
    Moller D, Moses A, Jones K, et al: Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. J Clin Endocrinol Metab. 68:499–504, 1989.PubMedCrossRefGoogle Scholar
  29. 29.
    Melmed S, Ziel F, Braunstein G, et al: Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. J Clin Endocrinol Metab. 67:395–399, 1988.PubMedCrossRefGoogle Scholar
  30. 30.
    Kvols L, Buck M, Moertel C, et al: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201–995). Ann Intern Med. 107:162–168, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Lamberts S: A guide to the clinical use of the somatostatin analogue SMS 201–995 (Sandostatin). Acta Endocrinol Suppl. 286:54–66, 1987.Google Scholar
  32. 32.
    Battershill P, Clissold S: Octreotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 38(5):658–702, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Daryl A. Cottrell
  • Samuel Cataland
  • Thomas O’Dorisio

There are no affiliations available

Personalised recommendations